Below is a list of the publications authored (or contributed to) by Alexander Shulgin, from 1961-2000. They are in order by date, beginning with the oldest.

1960's

• The psychotomimetic properties of 3,4,5-trimethoxyamphetamine.
  Shulgin, A. T., S. Bunnell, and T. Sargent. 1961.
  Nature 189: 10011-1012. 12
• Psychotomimetic agents related to mescaline.
  Shulgin, A. T. 1963.
  Experientia 19: 127. 19
• Composition of the myristicin fraction from oil of nutmeg.
  Shulgin, A. T. 1963.
  Nature 197: 379. 20
• Concerning the pharmacology of nutmeg.
  Shulgin, A. T. 1963.
  Mind 1: 299-302. 23
• 3-methoxy-4,5-methylenedioxy amphetamine, a new psychotomimetic agent.
  Shulgin, A. T. 1964.
  Nature 201: 1120-1121. 29
• Psychotomimetic amphetamines: methoxy 3,4-dialkoxyamphetamines.
  Shulgin, A. T. 1964.
  Experientia 20: 366. 30
• Isolation of methoxyeugenol and trans-isoelemicin from oil of nutmeg.
  Shulgin, A. T. and H. O. Kerlinger. 1964.
  Naturwissenschaften 15: 360-361. 31
• Synthesis of the trimethoxyphenylpropenes.
  Shulgin, A. T. 1965.
  Can. J. Chem. 43: 3437-3440. 43
• Possible implication of myristicin as a psychotropic substance.
  Shulgin, A. T. 1966.
  Nature 210: 380-384. 45
• The six trimethoxyphenylisopropylamines (trimethoxyamphetamines).
  Shulgin, A. T. 1966.
  J. Med. Chem. 9: 445-446. 46
• Role of 3,4-dimethoxyphenethylamin in schizophrenia.
  Shulgin, A. T., T. Sargent, and C. Naranjo. 1966.
  Nature 212: 1606-1607. 48
• The chemistry and psychopharmacology of nutmeg and of several related phenylisopropylamines.
  Shulgin, A. T., T. Sargent, and C. Naranjo. 1967.
  In D. H. Efron [ed.]: Ethnopharmacologic search for psychoactive drugs. U. S. Dept. of H. E. W., Public Health Service Publication No. 1645. Pp. 202-214. Discussion: ibid. pp. 223-229. 49
• Psychotropic phenylisopropylamines derived from apiole and dillapiole.
  Shulgin, A. T., and T. Sargent. 1967.
  Nature 215: 1494-1495. 50
• A note concerning the fate of the 4-methoxyl group in 3,4-dimethoxyphenethylamine (DMPEA).
  Sargent, T. W., D. M. Israelstam, A. T. Shulgin, S. A. Landaw, and N. N. Finley. 1967.
  Biochem. Biophys. Res. Commun. 29: 126-130. 52
• Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy.
  Naranjo, C., A. T. Shulgin, and T. Sargent. 1967.
  Med. Pharmacol. Exp. 17: 359-364. 53
• The ethyl homologs of 2,4,5-trimethoxyphenylisopropylamine.
  Shulgin, A. T. 1968.
  J. Med. Chem. 11: 186-187. 54
• Structure-activity relationships of one-ring psychotomimetics.
  Shulgin, A. T., T. Sargent, and C. Naranjo. 1969.
  Nature 221: 537-541. 57
• Recent developments in cannabis chemistry.
  Shulgin, A. T. 1969.
  J. Psyched. Drugs 2: 15-29. 58
• Psychotomimetic agents related to the catecholamines.
  Shulgin, A. T. 1969.
  J. Psyched. Drugs 2(2): 12-26. 59

1970's

• Chemistry and structure-activity relationships of the psychotomimetics.
  Shulgin, A. T. 1970.
  In D. H. Efron [ed.]. Psychotomimetic Drugs. Raven Press, New York. Pp. 21-41. 60
• The mode of action of psychotomimetic drugs; some qualitative properties of the psychotomimetics.
  Shulgin, A. T. 1970.
  Neur. Res. Prog. Bull. 8: 72-78. 61
• 4-alkyl-dialkoxy-alpha-methyl-phenethylamines and their pharmacologically-acceptable salts.
  Shulgin, A. T. 1970.
  U. S. Patent 3,547,999, issued Dec. 15, 1970. 63
• 4-bromo-2,5-dimethoxyphenylisopropylamine, a new centrally active amphetamine analog.
  Shulgin, A. T., T. Sargent, and C. Naranjo. 1971.
  Pharmacology 5: 103-107. 64
• Chemistry and sources.
  Shulgin, A. T. 1971.
  In S. S. Epstein [ed]. Drugs of abuse: their genetic and other chronic nonpsychiatric hazards. The MIT Press, Cambridge, Mass. Pp 3-26. 65
• Preliminary studies of the synthesis of nitrogen analogs of Delta₁-THC.
  Shulgin, A. T. 1971.
  Acta Pharm. Suec. 8: 680-681. 66
• Hallucinogens, CNS stimulants, and cannabis.
  Shulgin, A. T. 1972.
  In S. J. Mulé and H. Brill [eds.]: Chemical and biological aspects of drug dependence. CRC Press, Cleveland, Ohio. Pp. 163-175. 67
• Stereospecific requirements for hallucinogenesis.
  Shulgin, A. T. 1973.
  J. Pharm. Pharmac. 25: 271-272. 68
• Mescaline: the chemistry and pharmacology of its analogs.
  Shulgin, A. T. 1973.
  Lloydia 36: 46-58. 69
• The narcotic pepper - the chemistry and pharmacology of Piper methysticum and related species.
  Shulgin, A. T. 1973.
  Bull. Narc. 25: 59-74. Le poivre stupéfiant - chemie et pharmacologie de Piper methysticum et des espéces apparentées. Bull. Stupéfiants 25: 61-77. 70
• Animal pharmacology and human psychopharmacology of 3-methoxy-4,5-methylenedioxyphenylisopropylamine (MMDA).
  Shulgin, A. T., T. Sargent, and C. Naranjo. 1973.
  Pharmacology 10: 12-18. 71
• Human pharmacodynamics of the psychodysleptic 4-bromo-2,5-dimethoxyphenylisopropylamine labelled with [82]Br.
  Kalbhen, D. A., T. Sargent, A. T. Shulgin, G. Braun, H. Stauffer, N. Kusubov, and M. L. Nohr. 1974.
  IRCS (Int. Res. Comm. Sys.) 2: 1091. 73
• Drugs of abuse in the future.
  Shulgin, A. T. 1975
  Drug abuse in America Vol. 1. pp. 209-236. U.S.G.P.O. 5266-00004. Reprinted: Clin. Tox. 8: 405-456. 72
• A potential new brain-scanning agent: 4-[77]Br-2,5-dimethoxyphenylisopropylamine (4-Br-DPIA).
  Sargent, T., D. A. Kalbhen, A. T. Shulgin, H. Stauffer, and N. Kusubov. 1975
  J. Nucl. Med. 16: 243-245. 74
• Centrally active phenethylamines.
  Shulgin, A. T., and M. F. Carter. 1975.
  Psychopharm. Commun. 1: 93-98. 75
• In vivo human pharmacodynamics of the psychodysleptic 4-Br-2,5-dimethoxyphenylisopropylamine labelled with [82]Br or [77]Br.
  Sargent, T., D. A. Kalbhen, A. T. Shulgin, G. Braun, H. Stauffer, and N. Kusubov. 1975.
  Neuropharmacology 14: 165-174. 76
• The chemical catalysis of altered states of consciousness.
  Shulgin, A. T. 1975.
  Altered states of consciousness, current views and research problems. The drug abuse council, Washington, D. C. Pp. 123-134. 77
• Drug use and anti-drug legislation.
  Shulgin, A. T. 1975.
  The PharmChem Newsletter 4 (#8). 79
• Psychotomimetic phenylisopropylamines. 5. 4-alkyl-2,5-dimethoxyphenylisopropylamines.
  Shulgin, A. T., and D. C. Dyer. 1975.
  J. Med. Chem. 18: 1201-1204. 80
• Differentiation of PCP, TCP, and a contaminating precursor PCC, by thin layer chromatography.
  Shulgin, A. T., and C. Helisten. 1975.
  Microgram 8: 171-172. 81
• The detection of 1-piperidinodydlohexanecarbonitrile contamination in illicit preparations of 1-(1-phenylcyclohexyl)piperidine and 1-(1-(2-thienyl)cyclohexyl)piperidine.
  Helisten, C., and A. T. Shulgin.
  J. Chrom. 117: 232-235. 82
• Psychotomimetic agents.
  Shulgin, A. T. 1976.
  In M. Gordon [ed.] Psychopharmacological agents, Vol. 4. Academic Press, New York. Pp. 59-146. 83
• Abuse of the term "amphetamines".
  Shulgin, A. T. 1976.
  Clin. Tox. 9: 351-352. 84
• Profiles of psychedelic drugs. 1. DMT.
  Shulgin, A. T. 1976.
  J. Psychedelic Drugs 8: 167-168. 85
• Profiles of psychedelic drugs. 2. TMA-2.
  Shulgin, A. T. 1976.
  J. Psychedelic Drugs 8: 169. 86
• Illicit synthesis of phencyclidine (PCP) and several of its analogs.
  Shulgin, A. T., and D. E. MacLean. 1976.
  Clin. Tox. 9: 553-560. 87
• Sulfur analogs of psychotomimetic amines.
  Nichols, D. E., and A. T. Shulgin. 1976.
  J. Pharm. Sci. 65: 1554-1556. 89
• Quantitative measurement of demethylation of [14]C-methoxyl labeled DMPEA and TMA-2 in rats.
  Sargent, T., A. T. Shulgin, and N. Kusubov. 1976.
  Psychopharm. Commun. 2: 199-206. 90
• Phenylalkylamines with potential psychotherapeutic utility. 1. 2-amino-1-(2,5,-dimethoxy-4-methylphenyl)butane.
  Standridge, R. T., H. G. Howell, J. A. Gylys, R. A. Partyka, and A. T. Shulgin. 1976.
  J. Med. Chem. 19: 1400-1404. 91
• Profiles of psychedelic drugs. 3. MMDA.
  Shulgin, A. T. 1976.
  J. Psychedelic Drugs 8: 331. 92
• Profiles of psychedelic drugs. 4. Harmaline.
  Shulgin, A. T. 1977.
  J. Psychedelic Drugs 9: 79-80. 93
• Profiles of psychedelic drugs. 5. STP.
  Shulgin, A. T. 1977.
  J. Psychedelic Drugs 9: 171-172. 94
• Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives.
  Nichols, D. E., A. T. Shulgin, and D. C. Dyer. 1977.
  Life Sciences 21: 569-576. 95
• Mononethylthio analogues of 1-(2,4,5-trimethoxyphenyl)2-aminopropane.
  Jacob, P. III, G. Anderson III, C. K. Meshul, A. T. Shulgin, and N. Castagnoli Jr. 1977.
  J. Med. Chem. 20: 1235-1239. 96
• Mutagenic activity of some centrally active aromatic amines in Salmonella typhimurium.
  White, T. J., D. Goodman, A. T. Shulgin, N. Castagnoli Jr., R. Lee, and N. L. Petrakis. 1977.
  Mutation Research 56: 199-202. 97
• Synthesis and body distribution of several iodine-131 labeled centrally acting drugs.
  Braun, U., A. T. Shulgin, G. Braun, and T. Sargent III. 1977.
  J. Med. Chem. 20: 1543-1546. 98
• An iodated catecholamine congener for brain imaging and metabolic studies.
  Sargent, T. III, T. F. Budinger, G. Braun, A. T. Shulgin, and U. Braun. 1978.
  J. Nucl. Med. 19: 71-76. 99
• Psychotomimetic drugs: structure-activity relationships.
  Shulgin, A. T. 1978.
  In L. L. Iversen, S. D. Iversen, and S. H. Snyder [eds.], Handbook of psychopharmacology, Vol. 11. Plenum Press, New York. Pp. 243-333.
• Brain and retina uptake of a radio-iodine labeled psychotomimetic in dog and monkey.
  Sargent, T. III, G. Braun, U. Braun, T. F. Budinger, and A. T. Shulgin. 1978.
  Commun. Psychopharm. 2: 1-10. 101
• Synthesis of [123]I-labelled 4-iodo-2,5-dimethoxyphenylisopropylamine.
  Braun, G., A. T. Shulgin, and T. Sargent III. 1978.
  J. Labelled Comp. and Radiopharm. 14: 767-773. 102
• A novel illicit amphetamine laboratory.
  Murdock, J. E., J. R. Potty, and A. T. Shulgin. 1978.
  Microgram 11: 98-101. 103
• Absolute configuration and psychotomimetic activity.
  Anderson, G. M. III, G. Braun, U. Braun, D. E. Nichols, and A. T. Shulgin. 1978.
  In G. Barnett, M. Trsic, and R. Willette [eds.], QuaSAR Research Monograph 22. N.I.D.A. Washington, D.C. Pp. 8-15. 104
• Mescaline analogs: substitutions at the 4-position.
  Braun, U., G. Braun, P. Jacob III, D. E. Nichols, and A. T. Shulgin.
  In G. Barnett, M. Trsic, and R. Willette [eds.], QuaSAR Research Monograph 22. N.I.D.A. Washington, D.C. Pp. 27-37. 105
• 2-amino-1-(2,5-dimethoxyphenyl)butanes.
  Partyka, R. A., R. T. Standridge, H. G. Howell, and A. T. Shulgin. 1978.
  U.S. Patent 4,105,695, issued Aug. 8, 1978. 106
• Characterization of three new psychotomimetics.
  Shulgin, A. T., and D. E. Nichols. 1978.
  In R. C. Stillman and R. E. Willette [eds.], The psychopharmacology of hallucinogens. Pergamon Press, New York. Pp. 74-83. 107
• Molecular connectivity analysis of hallucinogenic mescaline analogs.
  Glennon, R. A., L. B. Kier, and A. T. Shulgin. 1979.
  J. Pharm. Sci. 68: 906-907. 108
• Chemistry of phenethylamines related to mescaline.
  Shulgin, A. T. 1979.
  J. Psychedelic Drugs 11: 41-52. 109
• Profiles of psychedelic drugs. 6. alpha,O-DMS.
  Shulgin, A. T. 1979.
  J. Psychedelic Drugs 11: 247. 110
• Profiles of psychedelic drugs. 7. Mescaline.
  Shulgin, A. T. 1979.
  J. Psychedelic Drugs 11: 355. 111

1980's

• Phenylalkylamines with potential psychotherapeutic utility. 2. Nuclear substituted 2-amino-1-phenylbutanes.
  Standridge, R. T., H. G. Howell, H. A. Tilson, J. H. Chamberlain, H. M. Holava, J. A. Gylys, R. A. Partyka, and A. T. Shulgin. 1980.
  J. Med. Chem. 23: 154-162. 112
• Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine).
  Braun, U., A. T. Shulgin, and G. Braun. 1980.
  J. Pharm. Sci. 69: 192-195. 113
• Study of the central nervous activity and anagesia of the N-substituted analogs of the amphet-amine derivative, 3,4-methylenedioxyphenyli-sopropyl-amine
  Braun, U., Shulgin, A. T. and Braun, G. 1980.
  Arzneim.-Forsch. 30:825-830.
• 5-methoxy-alpha-methyltryptamine (alpha,O-dimethylserotonine) a hallucinogenic homolog of serotonin.
  Kantor, R. E., S. D. Dudlettes, and A. T. Shulgin. 1980.
  Biol. Psychiat. 15: 349-352. 114
• Profiles of psychedelic drugs. 8. psilocybin.
  Shulgin, A. T. 1980.
  J. Psychedelic Drugs 12: 79. 115
• Prüfung auf Aktivität und Analgesia von N-substituierten Analogen des Amphetamin-Derivates 3,4-Methylendioxyphenylisopropylamin.
  Braun, U., A. T. Shulgin, and G. Braun. 1980.
  Arzneim. Forsch. 30: 825-830. 116
• Profiles of psychedelic drugs. 9. LSD.
  Shulgin, A. T. 1980.
  J. Psychedelic Drugs 12: 173-174. 117
• Hallucinogens.
  Shulgin, A. T. 1981.
  In: M. E. Wolff [ed.], Burger's medicinal chemistry. Wiley & Co. Pp. 1109-1137.
• Profiles of psychedelic drugs. 10. DOB.
  Shulgin, A. T. 1981.
  J. Psychoactive Drugs 13: 99. 119
• N,N-diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity.
  Shulgin, A. T., and M. F. Carter. 1981.
  Commun. Psychopharmacol. 4: 363-369. 120
• Sulfur analogues of psychotomimetic agents. Monothio analogues of mescaline and isomescaline.
  Jacob, P., and A. T. Shulgin. 1981.
  J. Med. Chem. 24: 1348. 121
• Photoelectron spectra of psychotropic drugs. 6. Relationships between physical properties and pharmacological actions of amphetamine analogues.
  Domelsmith, L. N., T. A. Eaton, K. N. Houk, G. M. Anderson, R. A. Glennon, A. T. Shulgin, N. Castagnoli, and P. A. Kollman. 1981.
  J. Med. Chem. 24: 1414. 122
• Chemistry of psychotomimetics.
  Shulgin, A. T. 1981.
  In F. Hoffmeister and G. Stille [eds.], Handbook of experimental pharmacology, Vol. 55/III. Springer-Verlag, Berlin Heidelberg. Pp. 3-29.
• Profiles of psychedelic drugs. 11. Bufotenine.
  Shulgin, A. T. 1981.
  J. Psychoactive Drugs 13: 389. 124
• Potential misrepresentation of 3,4-methylene-dioxyamphetamine (MDA). A toxicological warning.
  Shulgin, A. T., and P. Jacob. 1982.
  J. Anal. Tox. 6: 71. 127
• 1-(3,4-methylenedioxyphenyl)-3-aminobutane: a potential toxicological problem.
  Shulgin, A. T., and P. Jacob. 1982.
  J. Toxicol. - Clin. Toxicol. 19: 109. 12
• Sulfur analogues of psychotomimetic agents. 2. Analogues of (2,5-dimethoxy-4-methylphenyl)- and (2,5-dimethoxy-4-ethylphenyl)-isopropylamine.
  Jacob, P., and A. T. Shulgin. 1983.
  J. Med. Chem. 26: 746. 130
• Twenty years on an ever-changing quest.
  Shulgin, A. T. 1983.
  In L. Grinspoon and J. B. Bakalar [eds.], Psychedelic Reflections. Human Sciences Press, New York. 131
• New iodinated amphetamines by rapid synthesis for use as brain blood flow indicators.
  Sargent, T., A. T. Shulgin, and C. A. Mathis. 1982.
  J. Lab. Cmpds. and Radiopharm. 19: 1307. 132
• Sulfur analogues of psychotomimetic agents. 3. The ethyl homologues of mescaline and their monothio analogues.
  Jacob, P., and A. T. Shulgin. 1984.
  J. Med. Chem. 27: 881-888. 133
• Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography.
  Sargent, T., A. T. Shulgin, and C. A. Mathis. 1984.
  J. Med. Chem. 27: 1071-1077. 135
• Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents.
  Repke, D. B., D. B. Grotjahn, and A. T. Shulgin. 1985.
  J. Med. Chem. 28: 892. 136
• What is MDMA?
  Shulgin, A. T. 1985.
  PharmChem Newsletter 14: 3 (May-June, #3). 137
• Ring substituted beta-methoxyphenethylamines: a new class of psychotomimetic agents active in man.
  Lemaire, D., P. Jacob, and A. T. Shulgin. 1985.
  J. Pharm. Pharmacol. 37: 575. 138
• Iodine-122 labeled amphetamine derivatives with potential for PET brain blood-flow studies.
  Mathis, C. A., T. Sargent, and A. T. Shulgin. 1985.
  J. Nucl. Med. 26: 1295. 139
• Synthesis of 122-I and 125-I-labeled- meta-dimethoxy-N,N-dimethyliodophenylisopropylamines.
  Mathis, C. A., T. Sargent, and A. T. Shulgin. 1986.
  J. Labelled Comp. Radiopharm. 23: 115. 140
• A protocol for the evaluation of new psychoactive drugs.
  Shulgin, A. T., L. A. Shulgin, and P. Jacob. 1986.
  Methods and Findings in Experimental and Clinical Pharmacology 8: 313. 141
• Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class.
  Nichols, D. E., A. J. Hoffman, R. A. Oberlender, P. Jacob, and A. T. Shulgin. 1986.
  J. Med. Chem. 29: 2009. 143
• Determination of nicotine N-oxide by gas chromatography following thermal conversion to 2-methyl-6-(3-pyridyl)tetrahydro-1,2-oxazine.
  Jacob P 3rd, Benowitz NL, Yu L, Shulgin AT. 1986.
  Anal Chem. 1986 Sep;58(11):2218-21.
• [18]F-labelled N,N-dimethylamphetamine analogues for brain imaging studies.
  Mathis, C. A., A. T. Shulgin, Y. Yano, and T. Sargent. 1986.
  Appl. Radiat. Isot. 37: 865. 144
• The background and chemistry of MDMA.
  Shulgin, A. T. 1986.
  J. Psychoactive Drugs 18: 291-304. 145
• Rapid brain scanning pharmaceutical.
  Sargent, T. W., A. T. Shulgin, and C. A. Mathis. 1987.
  U. S. Patent 4,647,446. 146
• Autoradiographic localization of binding sites for [125]I-DOI, a new psychotomimetic radioligand, in the rat brain.
  McKenna, D. J., C. A. Mathis, A. T. Shulgin, T. Sargent, and J. M. Saavedra. 1987.
  Eur. J. Pharmacol. 137: 289-290. 147
• The 'social-chemistry' of pharmacological discovery.
  Shulgin, A. T. 1987.
  Social Pharmacology 1: 279-290. 148
• Reference information on MDMA.
  Shulgin, A. T. 1987.
  Analog 9: #4 (page 10). 149
• Identification and quantitative analysis of cotinine-N-oxide in human urine.
  Shulgin AT, Jacob P 3rd, Benowitz NL, Lau D. 1987.
  J Chromatogr. 1987 Dec 25;423:365-72.
• DIPT: the distortion of music.
  Shulgin, A. T. 1988.
  Reality Hackers #6 (Winter 1988) p. 27. 152.
• THE CONTROLLED SUBSTANCES ACT: A resource manual of the current status of the federal drug laws.
  Shulgin, A. T. 1988.
  383 pp., published in Lafayette, California 94549 April 1988. 154
• Recent studies of nicotine metabolism in humans.
  Jacob P 3rd, Benowitz NL, Shulgin AT. 1988.
  Pharmacol Biochem Behav. 1988 May;30(1):249-53.

1990's

• History of MDMA.
  Shulgin, A. T. 1990.
  [chapter] In S. Peroutka [ed.], Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA Kluwer Academic Publishers, Norwell, MA, 02061.
• [125I]-2-(2,5-dimethoxy-4-iodophenyl)aminoethane ([125I]-2C-I) as a label for the 5-HT2 receptor in rat frontal cortex.
  Johnson MP, Mathis CA, Shulgin AT, Hoffman AJ, Nichols DE. 1990.
  Pharmacol Biochem Behav. 1990 Jan;35(1):211-7.
• Cocaine smokers excrete a pyrolysis product, anhydroecgonine methyl ester.
  Jacob P 3rd, Jones RT, Benowitz NL, Shulgin AT, Lewis ER, Elias-Baker BA. 1990.
  J Toxicol Clin Toxicol. 1990;28(1):121-5.
• Synthesis of (3'R,5'S)-trans-3'-hydroxycotinine, a major metabolite of nicotine. Metabolic formation of 3'-hydroxycotinine in humans is highly stereoselective.
  Jacob P 3rd, Shulgin AT, Benowitz NL. 1990.
  J Med Chem. 1990 Jul;33(7):1888-91.
• PiHKAL: A Chemical Love Story
  Alexander & Ann Shulgin. 1991.
  Transform Press., Berkeley, CA.
• 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine.
  McKenna DJ, Guan XM, Shulgin AT. 1991.
  Pharmacol Biochem Behav. 1991 Mar;38(3):505-12.
• Gas chromatographic-mass spectrometric method for determination of anabasine, anatabine and other tobacco alkaloids in urine of smokers and smokeless tobacco users.
  Jacob P 3rd, Yu L, Liang G, Shulgin AT, Benowitz NL. 1993.
  J Chromatogr. 1993 Sep 8;619(1):49-61.
• Structure-activity relationships of the classic hallucinogens and their analogs.
  Jacob P 3rd, Shulgin AT. 1994.
  NIDA Res Monogr. 1994;146:74-91.
• Amphetamine, not MDMA, is associated with intracranial hemorrhage.
  Galloway G, Shulgin AT, Kornfeld H, Frederick SL. 1995.
  J Accid Emerg Med. 1995 Sep;12(3):231-2.
• TiHKAL: The Continuation
  Alexander & Ann Shulgin. 1991.
  Transform Press., Berkeley, CA.
• A New Vocabulary
  Alexander & Ann Shulgin. 1997.
  [chapter] in Entheogens and the Future of Religion. Robert Forte [ed.], CSP, San Francisco, CA.
• Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA).
  Parker MA, Marona-Lewicka D, Kurrasch D, Shulgin AT, Nichols DE. 1998.
  J Med Chem. 1998 Mar 12;41(6):1001-5.
• Methcathinone and 2-methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (methylone) selectively inhibit plasma membrane catecholamine reuptake transporters.
  Cozzi, N.V.; Sievert, M.K.; Shulgin, A.T.; Jacob III, P.; Ruoho, A.E. 1998.
  Soc. Neurosci. Abs., 24, 341.8 (1998)
• Methcathinone (MCAT) and 2-methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (MDMCAT) inhibit [3H]serotonin uptake into human platelets.
  Cozzi, N.V.; Shulgin, A.T.; Ruoho, A.E. 1998.
  Amer. Chem. Soc. Div. Med. Chem. Abs., 215, 152 (1998)
• Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes.
  Jacob P 3rd, Yu L, Shulgin AT, Benowitz NL. 1999.
  Am J Public Health. 1999 May;89(5):731-6.
• Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines.
  Cozzi NV, Sievert MK, Shulgin AT, Jacob P 3rd, Ruoho AE. 1999.
  Eur J Pharmacol. 1999 Sep 17;381(1):63-9.

2000's

• Overdose of 2.3 grams of intravenous methamphetamine: case, analysis and patient perspective
  Buffum JC, Shulgin AT. 2001
  J Psychoactive Drugs. 2001 Oct-Dec;33(4):409-12.
• Bruhn JG, EI-Seedi HR, Stephanson N, Beck O, Shulgin AT. "Ecstasy analogues found in cacti". Journal of psychoactive drugs, 40(2), 219-222. 2008.
• Cozzi NV, Gopalakrishnan A, Anderson LL, Feih JT, Shulgin AT, Daley PF, Ruoho AE. "Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter". Journal of neural transmission, 116(12), 1591-1599. 2009.
• Baumann MH, Ayestas MA, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AF, Cozzi NV. "The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue". Neuropsychopharmacology, 37(5), 1192-1203. 2009